In the face of unprecedented demand for healthcare services, traditional hospitals are easily overwhelmed. The Covid-19 pandemic has led to an unprecedented strain on healthcare systems worldwide, with a large influx of patients that present health issues ranging from mild infections better managed at home to life-threatening sepsis requiring immediate ICU-level care. In the United States, the available ICU-beds are numbered in the single digits for multiple states. In low- and middle-income countries, healthcare systems are often frailer with inherently lower capacity for both healthcare personnel and essential supplies. The suffering is also disproportionately borne by the most vulnerable: frontline healthcare workers, older adults in long-term assisted living facilities, and low-income individuals who delay necessary care for other conditions.
ANNE One is an FDA-cleared physiological monitoring platform that can provide early identification of disease across a wide range of applications. ANNE One is powered by predictive data analytics that allows for the rapid scaling of ICU-grade physiological monitoring for care anywhere. The ability to project care beyond hospital walls allows for tracking early signs of disease in vulnerable populations, monitoring those infected safely in a remote setting to protect precious hospital capacity and frontline workers, and to determine adequate recovery for a safe return to work.
5,000 patients have been monitored to date.
The medical monitoring platform is a $19.5 billion market. ANNE One’s system provides use cases that include detecting early infections in high-risk populations, supporting a safe transfer of care from hospitals to homes to preserve capacity and reduce unnecessary exposure to frontline healthcare workers, and tracking recovery of the sick to ensure a safe return to work. Generally, these systems can be used to not only remotely monitor patients anywhere with ICU-grade comprehensiveness, but to also alert users and healthcare providers of signs that may be suggestive of infection in an automated fashion.
Awarded Spinoff Prize in 2020 by Springer Nature.
Received 510(k) clearance from the U.S. Food and Drug Administration.
KT Corp of Korea signed a Memorandum of Understanding with Sibel Health to launch a pilot project and explore international business opportunities.
Sibel’s ANNE One seeks:
Joint development agreements to expand the use and deployment.
Connections to hospitals and other existing institutions that can deploy ANNE One.